# APG-2449 in Patients With Advanced Solid Tumors

> **NCT03917043** · PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 165 (estimated)

## Conditions studied

- Advanced Solid Cancer
- Non Small Cell Lung Cancer
- Esophageal Cancer
- Ovarian Cancer
- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** APG-2449

## Key facts

- **NCT ID:** NCT03917043
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-27
- **Primary completion:** 2027-12
- **Final completion:** 2028-01
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03917043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03917043, "APG-2449 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03917043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*